The company's exam, CORA, uses advanced signal processing algorithms to analyze two newly discovered biomarkers in the heart's electrical activity, which can accurately evaluate a patient's risk of having coronary artery disease. CORA's early detection can prevent sudden cardiac deaths and lower the costs of cardiovascular-related illnesses. AccuLine has received a grant from the Israeli Innovation Authority and is a portfolio company of eHealth Ventures, which is partnered with Mayo Clinic and backed by Amgen, Medison Ventures, and SCI.